Long-term efficacy and immune responses following immunization with the RTS,S malaria vaccine

J. A. Stoute; K. E. Kester; U. Krzych; B. T. Wellde; T. Hall; K. White; G. Glenn; C. F. Ockenhouse; N. Garcon; R. Schwenk; D. E. Lanar; P. Sun; P. Momin; R. A. Wirtz; C. Golenda; M. Slaoui; G. Wortmann; C. Holland; M. Dowler; J. Cohen; W. R. Ballou

doi:10.1086/515657

Long-term efficacy and immune responses following immunization with the RTS,S malaria vaccine

J. A. Stoute, K. E. Kester, U. Krzych, B. T. Wellde, T. Hall, K. White, G. Glenn, C. F. Ockenhouse, N. Garcon, R. Schwenk, D. E. Lanar, P. Sun, P. Momin, R. A. Wirtz, C. Golenda, M. Slaoui, G. Wortmann, C. Holland, M. Dowler, J. CohenW. R. Ballou

Research output: Contribution to journal › Article › peer-review

226 Scopus citations

Abstract

The malaria sporozoite vaccine candidate RTS,S, formulated with an oil- in-water emulsion plus the immunostimulants monophosphoryl lipid A and the saponin derivative QS21 (vaccine 3), recently showed superior efficacy over two other experimental formulations. Immunized volunteers were followed to determine the duration of protective immune responses. Antibody levels decreased to between one-third and one-half of peak values 6 months after the last dose of vaccine. T cell proliferation and interferon-γ production in vitro were observed in response to RTS,S or hepatitis B surface antigen. Seven previously protected volunteers received sporozoite challenge, and 2 remained protected (1/1 for vaccine 1, 0/1 for vaccine 2, and 1/5 for vaccine 3). The prepatent period was 10.8 days for the control group and 13.2 days for the vaccinees (P < .01). Immune responses did not correlate with protection. Further optimization in vaccine composition and/or immunization schedule will be required to induce longer-lasting protective immunity.

Original language	English (US)
Pages (from-to)	1139-1144
Number of pages	6
Journal	Journal of Infectious Diseases
Volume	178
Issue number	4
DOIs	https://doi.org/10.1086/515657
State	Published - 1998

All Science Journal Classification (ASJC) codes

General Medicine

Access to Document

10.1086/515657

Cite this

Stoute, J. A., Kester, K. E., Krzych, U., Wellde, B. T., Hall, T., White, K., Glenn, G., Ockenhouse, C. F., Garcon, N., Schwenk, R., Lanar, D. E., Sun, P., Momin, P., Wirtz, R. A., Golenda, C., Slaoui, M., Wortmann, G., Holland, C., Dowler, M., ... Ballou, W. R. (1998). Long-term efficacy and immune responses following immunization with the RTS,S malaria vaccine. Journal of Infectious Diseases, 178(4), 1139-1144. https://doi.org/10.1086/515657

@article{0e0f523066914cb4ad0b846c085a0101,

title = "Long-term efficacy and immune responses following immunization with the RTS,S malaria vaccine",

abstract = "The malaria sporozoite vaccine candidate RTS,S, formulated with an oil- in-water emulsion plus the immunostimulants monophosphoryl lipid A and the saponin derivative QS21 (vaccine 3), recently showed superior efficacy over two other experimental formulations. Immunized volunteers were followed to determine the duration of protective immune responses. Antibody levels decreased to between one-third and one-half of peak values 6 months after the last dose of vaccine. T cell proliferation and interferon-γ production in vitro were observed in response to RTS,S or hepatitis B surface antigen. Seven previously protected volunteers received sporozoite challenge, and 2 remained protected (1/1 for vaccine 1, 0/1 for vaccine 2, and 1/5 for vaccine 3). The prepatent period was 10.8 days for the control group and 13.2 days for the vaccinees (P < .01). Immune responses did not correlate with protection. Further optimization in vaccine composition and/or immunization schedule will be required to induce longer-lasting protective immunity.",

author = "Stoute, {J. A.} and Kester, {K. E.} and U. Krzych and Wellde, {B. T.} and T. Hall and K. White and G. Glenn and Ockenhouse, {C. F.} and N. Garcon and R. Schwenk and Lanar, {D. E.} and P. Sun and P. Momin and Wirtz, {R. A.} and C. Golenda and M. Slaoui and G. Wortmann and C. Holland and M. Dowler and J. Cohen and Ballou, {W. R.}",

year = "1998",

doi = "10.1086/515657",

language = "English (US)",

volume = "178",

pages = "1139--1144",

journal = "Journal of Infectious Diseases",

issn = "0022-1899",

publisher = "Oxford University Press",

number = "4",

}

Stoute, JA, Kester, KE, Krzych, U, Wellde, BT, Hall, T, White, K, Glenn, G, Ockenhouse, CF, Garcon, N, Schwenk, R, Lanar, DE, Sun, P, Momin, P, Wirtz, RA, Golenda, C, Slaoui, M, Wortmann, G, Holland, C, Dowler, M, Cohen, J & Ballou, WR 1998, 'Long-term efficacy and immune responses following immunization with the RTS,S malaria vaccine', Journal of Infectious Diseases, vol. 178, no. 4, pp. 1139-1144. https://doi.org/10.1086/515657

TY - JOUR

T1 - Long-term efficacy and immune responses following immunization with the RTS,S malaria vaccine

AU - Stoute, J. A.

AU - Kester, K. E.

AU - Krzych, U.

AU - Wellde, B. T.

AU - Hall, T.

AU - White, K.

AU - Glenn, G.

AU - Ockenhouse, C. F.

AU - Garcon, N.

AU - Schwenk, R.

AU - Lanar, D. E.

AU - Sun, P.

AU - Momin, P.

AU - Wirtz, R. A.

AU - Golenda, C.

AU - Slaoui, M.

AU - Wortmann, G.

AU - Holland, C.

AU - Dowler, M.

AU - Cohen, J.

AU - Ballou, W. R.

PY - 1998

Y1 - 1998

N2 - The malaria sporozoite vaccine candidate RTS,S, formulated with an oil- in-water emulsion plus the immunostimulants monophosphoryl lipid A and the saponin derivative QS21 (vaccine 3), recently showed superior efficacy over two other experimental formulations. Immunized volunteers were followed to determine the duration of protective immune responses. Antibody levels decreased to between one-third and one-half of peak values 6 months after the last dose of vaccine. T cell proliferation and interferon-γ production in vitro were observed in response to RTS,S or hepatitis B surface antigen. Seven previously protected volunteers received sporozoite challenge, and 2 remained protected (1/1 for vaccine 1, 0/1 for vaccine 2, and 1/5 for vaccine 3). The prepatent period was 10.8 days for the control group and 13.2 days for the vaccinees (P < .01). Immune responses did not correlate with protection. Further optimization in vaccine composition and/or immunization schedule will be required to induce longer-lasting protective immunity.

AB - The malaria sporozoite vaccine candidate RTS,S, formulated with an oil- in-water emulsion plus the immunostimulants monophosphoryl lipid A and the saponin derivative QS21 (vaccine 3), recently showed superior efficacy over two other experimental formulations. Immunized volunteers were followed to determine the duration of protective immune responses. Antibody levels decreased to between one-third and one-half of peak values 6 months after the last dose of vaccine. T cell proliferation and interferon-γ production in vitro were observed in response to RTS,S or hepatitis B surface antigen. Seven previously protected volunteers received sporozoite challenge, and 2 remained protected (1/1 for vaccine 1, 0/1 for vaccine 2, and 1/5 for vaccine 3). The prepatent period was 10.8 days for the control group and 13.2 days for the vaccinees (P < .01). Immune responses did not correlate with protection. Further optimization in vaccine composition and/or immunization schedule will be required to induce longer-lasting protective immunity.

UR - http://www.scopus.com/inward/record.url?scp=17344368403&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=17344368403&partnerID=8YFLogxK

U2 - 10.1086/515657

DO - 10.1086/515657

M3 - Article

C2 - 9806046

AN - SCOPUS:17344368403

SN - 0022-1899

VL - 178

SP - 1139

EP - 1144

JO - Journal of Infectious Diseases

JF - Journal of Infectious Diseases

IS - 4

ER -

Long-term efficacy and immune responses following immunization with the RTS,S malaria vaccine

Abstract

All Science Journal Classification (ASJC) codes

Access to Document

Other files and links

Fingerprint

Cite this